2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Clinical Procedures, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pregnant, Young Adult
PAPER

3792 Clinical features, outcome prediction and disease monitoring by cell-free DNA in adult patients with langerhans cell histiocytosis and erdheim-chester disease

Long Chang, MD, Wei-tong Liu2, Jiayi Liu3, Dao-Bin Zhou4, Xinxin Cao, MD5
1 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
2 Department of Medical Oncology, National Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
3 Department of Medical Oncology, National Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
4 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
5 Department of Medical Oncology, National Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Background

Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) are rare histiocytic neoplasms driven by MAPK pathway gene mutations presenting with a variety of clinical manifestations. Cell-free DNA (cfDNA) is becoming a widely used prognostic and predictive biomarker in oncology. This study investigated the detection of the mutations in cfDNA at diagnosis and during follow-up in adult histiocytosis cohort to clarify the associations between the clinical features, outcome and prognosis value.

 

Methods

Two hundred and two adult patients (age ≥18 years) diagnosed with LCH and 46 patients with ECD were included in this study. Lesion biopsy samples of enrolled patients were subjected to next-generation sequencing (NGS).The presence and level of genetic alternations of plasma cfDNA in the MAPK pathway were detected by QX200TM Droplet Digital PCR System (Bio-Rad).

Results

Among the patients with LCH, the median age at diagnosis was 35 years (IQR, 28-44 years) in this study. One hundred and sixty patients (79.2%) were treatment- naïve, and 42 patients (20.8%) were refractory or relapsed. The patients were classi?ed into three groups: the unifocal group (n=47, 23.3%), single system multifocal (SS-m) group (n=30, 14.9%), and multisystem (MS) group (n=125, 61.9%). For patients with ECD, with the median age at diagnosis 50 years (IQR, 43-58 years). Forty-one of them (89.1%) were newly diagnosed.

Sequencing of tissue NGS and plasma cfDNA was underwent successfully in each patient, and a total of 70 LCH patients and 37 ECD patients had detectable cfDNA an baseline, with the sensitivity of 34.6% and 78.2%, respectively. cfDNA positivity rates differed by mutation subtype, with BRAFV600E, BRAFindel, and MAP2K1 alternations in LCH patients 33.3% (33/100), 53.7% (22/41), and 43.3% (13/30), respectively. The positivity rates of BRAFV600E and MAP2K1 alternations in ECD patients was 88.6% (31/35) and 100% (1/1), significantly higher than those in LCH patients (P<0.0001).

A higher frequency of detectable cfDNA was found in patients with MS LCH (58/125, 46.4%) compared to unifocal (7/47, 14.8%) and SS-m disease (5/30, 16.7%) (p<0.001). The frequency of positive cfDNA was also significantly associated with status of disease: more common in patients with refractory/relapsed disease (27/42, 64.3%) than in patients with newly diagnosed disease (43/160, 26.9%) (p<0.001).Compared with patients without organ involvement, thyroid (OR, 6.79; P < 0.001), risk organ (OR, 4.74; P < 0.001), skin (OR, 4.74; P < 0.001), pituitary (OR, 4.16; P < 0.001), and lymph node (OR, 3.54; P < 0.001) involvement was significantly associated with cfDNA positivity.

Patients with detective cfDNA had significantly higher levels of following measured inflammatory markers, including hsCRP (median 1.60 vs. 6.29 mg/L, p<0.0001), ESR (8 vs. 18 mm/h, p=0.0001), Fbg (3.04 vs. 3.72 g/L, p<0.0001), IL-6 (3.76 vs. 6.31 pg/mL, p=0.0046), IL-10 (3.01 vs. 5.00 pg/mL, p=0.0065), and TNF-α (7.20 vs. 11.20 pg/mL, p=0.0003).

After a median follow-up of 23 (IQR 10-33 months) months, 22 LCH patients (10.8%) experienced disease relapse while one death was observed. Patients who had positive cfDNA at baseline showed poorer outcomes (median PFS 49.7 months vs. not reached, p<0.001). For ECD patients, 7 patients (10.8%) experienced disease relapse 6 patients died. Patients who had high cfDNA concentration at baseline (VAF>0.8%) was an adverse prognostic factor for PFS (median PFS 32.6 months vs. not reached, p=0.049). One hundred and ten patients with LCH were evaluated after system therapy. The cfDNA-positive group exhibited a substantially lower ORR than the cfDNA-negative group (71.4% vs. 95.1%, p < 0.001).

A dynamic longitudinal analysis of cfDNA was performed in 73 LCH and 22 ECD patients who received systemic therapy. Complete clearance of cfDNA occurred in 60 patients (27.4%), which was strongly associated with higher ORR (90.0% vs. 61.5%, p=0.021) and better outcomes (median PFS not reached vs. 19.6 months, P=0.006).

Conclusion

Positive cfDNA at baseline was associated multiple system involvement, refractory/relapsed status, hyperinflammatory state, poor treatment response and outcomes in adult patients with LCH. Early clearance in LCH patients after therapy predict poor treatment response and outcomes. ECD patients with lung involvement had significantly higher median baseline cfDNA levels. High cfDNA concentration at baseline was an adverse prognostic factor in ECD patients.

Long Chang, MD: No relevant conflicts of interest to declare.